Építés alatt – nem éles oldal
Belépés
Résztvevőt keres itt: BelgiumFázis nélkül

Evaluating How a Tinnitus Implant Affects Tinnitus Loudness in Adults With Chronic Tinnitus and Varying Levels of Hearing Loss

A legfontosabb adatok

Ki végzi
Cochlear
Hol
Edegem (Belgium)A helyszín megnézéseMég 1 másik országban, 1 helyszínen
Azonosító
Állapot
Toboroz
Résztvevők
16 fő, tervezett
Kezdés
2025. jún. 16.
Várható befejezés
2027. júl.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • Tinnitus Implant System
A regiszteradat frissítve
2026. június 2.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for adults with severe, long-lasting ringing in the ears (tinnitus) that other care has not helped. They may have normal hearing up to moderately severe hearing loss. The trial tests an implanted device.

Életkor
18 years or older.
Nem
All sexes can join.
A betegség stádiuma
Tinnitus in one ear, or worse in one ear, lasting at least 6 months. It must not beat with the pulse. Severe loudness: VAS-L score 50-100/100 and TFI score 52-90/100. Hearing: average hearing level less than 65 dB HL in each ear, and speech-sound recognition of 80% or more in each ear with the hearing aid setting that gives the highest score.
Korábbi kezelés
Tinnitus has not improved enough with standard care such as CBT (talking therapy) or a hearing aid, when these were medically needed. People cannot join if they used antidepressant, anxiety, antipsychotic, antiepileptic or other nerve-acting drugs, or other tinnitus treatments, now or in the 2 months before. Low doses for sleep or occasional use for anxiety are allowed.
Biomarker vagy leletérték
Tinnitus loudness (VAS-L) must drop by 15/100 points or more during a test where the inner ear is stimulated electrically through the eardrum.

A részvétel fő kizáró okai

  • Tinnitus that beats with the pulse.
  • Problems in the structure of the inner ear, hearing nerve or brainstem seen on CT or MRI.
  • Past brain or major ear surgery, brain or temporal bone tumours, repeated ear infections in the last year, otosclerosis, or major head injury with lasting brain damage.
  • Depression or anxiety (PHQ-9 above 9 or GAD-7 above 9).
  • Being pregnant or breastfeeding.

A regiszter feltételei, szó szerint

Mind a 21 feltétel megnézéseKevesebb

Ki vehet részt

  • 18 years or older
  • Normal hearing to moderately severe sensorineural hearing loss defined as a pure tone average (PTA) at 500, 1000, 2000 and 4000 Hz less than 65 dB HL in both ears (separately) and best-aided phoneme recognition score more than or equal to 80% in both ears (separately)
  • Unilateral or asymmetric subjective (no pulsatile) tinnitus. In case of asymmetric tinnitus, the worst ear must be implanted
  • Tinnitus duration of at least 6 months
  • Severe tinnitus loudness determined by a. VAS-L score in the severe range i.e. 50-100/100 b. TFI score in the severe range i.e. 52-90/100
  • Tinnitus that is intractable and has not been ameliorated satisfactorily by standard of care such as CBT or hearing aid, when such interventions are potentially clinically indicated
  • Clinically significant reduction in VAS-L score (≥ 15/100 points) in response to trans-tympanic promontory stimulation
  • Willing and able to provide written informed consent
  • Medically able to use the device and to undergo general anaesthesia for implantation taking into account their medical condition, contraindications and surgical risks
  • Dutch language proficiency

Ki nem vehet részt

  • Medical contraindications limiting correct placement, activation, or treatment (determined by medical history; contraindications include brain or major ear surgery, brain or temporal bone tumor(s), recurrent ear infections within the last year, otosclerosis, prior major head trauma that results in sudden injury that causes damage to the brain and results in lasting cognitive impairment)
  • Active (currently or within two months prior to enrolment) use of medications (taking regularly scheduled antidepressant, anxiolytic, antipsychotic or antiepileptic medications, or other neuromodulator agents) or other tinnitus treatments
  • It is permissible to include people who use such medications at lower doses as a sleep aid or for people who intermittently use such medications for situational anxiety (e.g., Ativan before airplane travel). A change in medication during the trial should be avoided
  • Current participation, or participation in another interventional clinical study/trial in the past 60 days, involving an investigational drug or device (unless the other investigation was/is a Cochlear sponsored investigation and determined by the investigator or Sponsor to not impact this investigation)
  • Any medical condition, including mental illness or substance abuse, deemed by the Investigator to likely interfere with a patient's ability to sign informed consent, cooperate and/or participate in the study, or interfere with the interpretation of the results (incl. pregnant or breastfeeding women or patients with unrealistic expectations)
  • Any anatomical or structural abnormalities of the inner ear, cochlear nerve, or brainstem that would negatively impact response to study intervention (determined in a temporal bone CT and if necessary (e.g. possibility of vestibular/acoustic schwannoma) by a MRI scan of the head (of sufficient quality at the discretion of the investigator) not more than five years old at the time of enrolment
  • Pulsatile tinnitus
  • Presence of clinically diagnosed depression or anxiety determined by a psychological state evaluation (if PHQ-9 > 9 or GAD-7 > 9)
  • It is permissible to include people who prefer to use a hearing aid to amplify ipsilateral hearing loss. The start of using a hearing aid during the trial should be avoided
  • Investigator site personnel directly affiliated with this study and/or their immediate families; immediate family is defined as a spouse, parent, child, or sibling
  • Cochlear employees or employees of Contract Research Organizations or contractors engaged by Cochlear for the purposes of this investigation

Helyszínek itt: Belgium

Még 1 másik országban, 1 helyszínen

  • Antwerp University Hospital (UZA)Edegem, BelgiumContact: Prof. Dr. Marc LammersRésztvevőt keres

A vizsgálatról

Mit akar kideríteni a vizsgálat

This study will test an experimental Tinnitus Implant System that consists of a cochlear implant, sound processor and programming software. The Tinnitus implant is surgically placed under the skin just behind the ear in the mastoid bone. It has an electrode that extends from the implant into the promontory bone of the cochlea which emits electrical signals that stimulate the auditory nerve. The sound processor is worn behind the ear and powers the implant via the coil. The study will be conducted in adults with moderate to severe chronic tinnitus who have normal hearing to moderately severe hearing loss in the inner ear. The study participants will undergo a series of tests that include evaluations of tinnitus loudness and annoyance, and self-reported questionnaires on their tinnitus and general health.

A vizsgálat csoportja

  • Tinnitus Implant SystemA vizsgált kezelés

    Tinnitus Implant

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Prospective, Multicentric, Feasibility Investigation to Assess the Effect of the Tinnitus Implant on Tinnitus Loudness in Adults With Moderate to Severe Chronic Tinnitus Accompanied by Normal Hearing to Moderately Severe Hearing Loss.
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
A regiszteradat frissítve
2026. június 2.